INTERIM REPORT FOR THE PERIOD JANUARY 1 – JUNE 30, 2005
Improved profitability and key agreements with AstraZeneca, Nordea and VolvoFirst half year 2005 compared with first half year 2004 • Net sales amounted to SEK 325 million (326). • Operating profit amounted to SEK 21 million (15), generating an operating margin of 7% (5). • Profit after tax was SEK 21 million (13), an increase of 62%. • Earnings per share for the period amounted to SEK 0.36 (0.23). • Cash flow from operating activities amounted to SEK 23 million (-22). • Partnership agreement with AstraZeneca. Extended general agreements with Ericsson and Volvo. Important agreements also